| 0.6798 0.04 (6.17%) | 09-09 12:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.88  |
1-year : | 0.99 |
| Resists | First : | 0.75 |
Second : | 0.85 |
| Pivot price | 0.7 |
|||
| Supports | First : | 0.61 |
Second : | 0.5 |
| MAs | MA(5) : | 0.65 |
MA(20) : | 0.71 |
| MA(100) : | 1.01 |
MA(250) : | 1.3 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 17.1 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 3.15 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ESLA ] has closed above bottom band by 33.3%. Bollinger Bands are 54.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.71 - 0.71 | 0.71 - 0.72 |
| Low: | 0.61 - 0.61 | 0.61 - 0.62 |
| Close: | 0.63 - 0.64 | 0.64 - 0.65 |
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Tue, 08 Sep 2026
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Fri, 21 Aug 2026
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Sun, 16 Aug 2026
Estrella Immunopharma (ESLA) Holds Ground at $0.72 as Immunotherapy Pipeline Takes Center Stage - Long Short Pair - vinanet.vn
Sat, 15 Aug 2026
Estrella Immunopharma Inc. (NASDAQ: ESLA) Share Price, ESLA Stock News, ESLA Share Price & Updates - Kalkine
Fri, 14 Aug 2026
Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 60.4 (%) |
| Held by Institutions | 11.1 (%) |
| Shares Short | 61 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -251.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -2.72 |
| PEG Ratio | 0 |
| Price to Book value | -4 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|